【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於有骨折風險之老年人(除非用於癲癇、調節情緒)。

As monotherapy or adjunctive therapy in the treatment of partial seizure in adults and child with epilepsy

oxcarbazepine and its active metabolite (MHD) is thought to be mainly based on blockade of voltage-sensitive sodium channels, thus resulting in stabilization of hyper excited neural membranes, inhibition of repetitive neuronal firing, and diminishment of propagation of synaptic impulses.

Oxcarbazepine is completely absorbed; food has no effect on rate or extent. It is converted into active metabolite (MHD) in liver; about 40% of MHD is bound to serum proteins, mainly albumin. MHD is eliminated primarily by glucuronidation to inactive products (47%) and renal excretion of unchanged MHD (27%). Elimination half-life: oxcarbazepine 2.4±1.1 hr; MHD: 9.3±1.8 hr; renal impairment (Clcr ＜30 ml/min): MHD: 19 hr.

Hypersensitivity to oxcarbazepine

C

Avoided

dizziness, headache, somnolence, nausea, vomiting, fatigue (very common, >10%), hyponatremia (common, >1%)

Adult: 600mg as initiated dose given in 2 divided doses, increased by 600mg/ day at weekly interval. Children>3 yrs: Initiated dose 8~10mg/kg/ day given in 2 divided doses, increased by 10mg/kg/ day at weekly interval.